| HIV-negative | HIV-1 | HIV-2 | HIV-1 + HIV-2 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Age group* | MR†(deaths/pyo) | MR†(deaths/pyo) | MRR‡ | 95% CI§ | MR†(deaths/pyo) | MRR‡ | 95%CI§ | MR†(deaths/pyo) | MRR‡ | 95%CI§ |
MEN | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
35–44 | 4.7(4/844) | 100(1/10) | 21.1 | 2.4,189 | 17.9(2/112) | 3.8 | 0.7,20.6 | 0(0/12.1) |  |  |
45–54 | 20.9(28/1342) | 235(2/8.5) | 10.3 | 2.7,47.3 | 46.9(9/192) | 2.2 | 1.1,4.8 | 320(2/6.3) | 15.3 | 3.6,64.3 |
55–64 | 45.5 (81/1781) | 0 (0/4.6) |  |  | 81.7(18/220) | 1.8 | 1.1,3.0 | 0 (0/5.3) |  |  |
65–74 | 88.2 (65/737) | 268(1/3.7) | 3.0 | 0.4,21.9 | 124 (13/104) | 1.4 | 0.8,2.6 | 0 (0/0) |  |  |
75+ | 134 (51/380) | 0 (0/0) | Â | Â | 0(0/19.9) | Â | Â | 0 (0/0) | Â | Â |
Total: | 45.0(229/5084) | 148.8(4/26.9) | 5.2 # | 1.9,14.0 | 64.8(42/648) | 1.6 # | 1.1, 2.2 | 84.3 (2/23.7) | 4.3 # | 1.1,17.3 |
WOMEN | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
35–44 | 1.9 (2/1040) | 0(0/11.3) |  |  | 33.3(6/180) | 17.4 | 3.5,86.0 | 97.7(1/10.2) | 50.8 | 4.6,560 |
45–54 | 13.3 (18/1346) | 227(2/8.8) | 17.0 | 3.9,73.1 | 19.3(6/311) | 1.4 | 0.6,3.6 | 57.4(1/17.4) | 4.3 | 0.6,32.1 |
55–64 | 31.7 (57/1798) | 74.3(1/13.5) | 2.3 | 0.3,16.9 | 91.8(33/359) | 2.9 | 1.9,4.4 | 485(1/2.1) | 15.3 | 2.1,110 |
65–74 | 63.8 (55/862) | 0(0/0) |  |  | 73.9(11/149) | 1.2 | 0.6,2.2 | 0 (0/0) |  |  |
75+ | 110 (39/352) | 0(0/0) | Â | Â | 174(7/40.2) | 1.6 | 0.7,3.5 | 0 (0/0) | Â | Â |
Total: | 31.7(171/5398) | 89.3 (3/33.6) | 4.7 # | 1.5,14.6 | 60.6(63/1040) | 2.1 # | 1.6,2.8 | 101(3/29.7) | 7.9 # | 2.5,24.9 |